Navigation path

Themes
Agriculture & food
Energy
Environment
ERA-NET
Health & life sciences
Human resources & mobility
Industrial research
Information society
Innovation
International cooperation
Nanotechnology
Pure sciences
Research infrastructures
Research policy
Science & business
Science in society
Security
SMEs
Social sciences and humanities
Space
Special Collections
Transport

Countries
Countries
  Argentina
  Australia
  Austria
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Chile
  China
  Colombia
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece
  Hungary
  Iceland
  India
  Indonesia
  Ireland
  Israel
  Italy
  Jamaica
  Japan
  Kazakhstan
  Kenya
  Korea
  Latvia
  Lichtenstein
  Lithuania
  Luxembourg
  Madagascar
  Malaysia
  Malta
  Mexico
  Montenegro
  Morocco
  Mozambique
  Namibia
  Netherlands
  New Zealand
  Nigeria
  Norway
  Panama
  Peru
  Poland
  Portugal
  Romania
  Russia
  Senegal
  Serbia
  Slovakia
  Slovenia
  South Africa
  Spain
  Sri Lanka
  Swaziland
  Sweden
  Switzerland
  Taiwan
  Tanzania
  Thailand
  Tunisia
  Turkey
  Uganda
  Ukraine
  United Kingdom
  United States
  Vietnam


   Infocentre

Last Update: 14-12-2011  
Related category(ies):
Health & life sciences  |  Research policy

 

Add to PDF "basket"

NEUROSTEMCELL advances stem cell therapy research

Maximising prospects for successful clinical trials of stem cell therapy for neurodegenerative diseases such as Huntington's and Parkinson's is possible through solid cooperation between experimental and clinical researchers. The NEUROSTEMCELL ('European consortium for stem cell therapy for neurodegenerative disease') project is driving this effort, and positive results are already coming in. NEUROSTEMCELL is supported under the Health Theme of the EU's Seventh Framework Programme (FP7) to the tune of EUR 11.9 million.

Stem cell therapy advances © Shutterstock
Stem cell therapy advances
©  Shutterstock

Both Huntington's and Parkinson's diseases are triggered by the degeneration of specific types of brain neurons: striatal neurons in Huntington's and dopaminergic neurons in Parkinson's. Led by Professor Elena Cattaneo at the Università degli Studi di Milano in Italy, the NEUROSTEMCELL consortium comprises 13 research institutions and 3 small and medium-sized enterprises (SMEs) from 6 EU Member States as well as the United States. Developing safe and validated cells and clinical grade reagents (specifically for dopaminergic and striatal neurons that may be transplanted into patients) to be used in clinical trials and eventually also in drug discovery is the ultimate objective. Their work is proving fruitful for the team and for Europe as well.

In their latest development, the NEUROSTEMCELL team devised a novel strategy for the efficient transformation of human pluripotent stem cells (PSCs) into dopamine-producing neurons. These neurons can be implanted into animals where they show 'robust performance' by establishing new connections and achieving long-term survival. The outcome is advancement in the use of PSCs, helping develop new therapies for neurodegenerative diseases.

The project partners say the regulatory, ethical and societal issues linked to the use of stem cells for therapy are being considered as science advances from bench to bedside. The team notes how Huntington's and Parkinson's are ideal candidate diseases for restorative stem-cell–based therapies. The pathology of both diseases progresses slowly; it is characterised by the preferential loss of one type of neuron, the GABAergic medium-sized spiny neurons in Huntington's and the mesencephalic dopamine (mesDA) neurons in Parkinson's. The cell replacement strategy targets the substitution of the lost GABA and mesDA neurons by implanting new functional cells.

The NEUROSTEMCELL project is targeting the identification and systematic comparison of progenitor cell lines with the most favourable characteristics for mesDA and striatal GABAergic neuronal differentiation. These cell lines are derived either from human embryonic stem (ES) cells, from neural stem (NS) cells derived from ES cells or foetal brain, from induced pluripotent stem (iPS) cells or from in vitro short-term expanded neural progenitors from ventral midbrain grown as neurospheres (VMN, ventral midbrain neurospheres). The project team is performing rigorous and systematic testing of the most prominent candidate cells in appropriate animals models.

The partners are identifying procedures and safety systems that will enable full elimination of proliferative and/or tumour-forming cells from the graft cell preparations. They are also applying in vivo imaging tools for non-invasive monitoring of the survival and growth of the grafted cells, and they are developing criteria, procedures and protocols for reproducible, safe and large-scale manufacture of stem cells and their progeny to clinical-grade standard. The team is also establishing a banked stock of validated, safety-qualified and traceable cells for clinical use, as well as developing clinical protocols for use in phase-I trials in patients with Huntington's and Parkinson's.

Ethical and safety criteria are being established for guiding implementation of stem cell therapies in the clinic, and the team is also developing an interface with bio-industry and a product-specific regulatory strategy that is compatible with a future marketing authorisation. And finally, the NEUROSTEMCELL partners are providing information to both patient groups and laypersons about advances in the field, and about what steps will be taken to ensure success.

NEUROSTEMCELL partner Lorenz Studer of the Sloan-Kettering Institute for Cancer Research Corporation in the United States notes that while the results are encouraging, more work is needed.

'We are now gearing up to produce dopaminergic cells under conditions that would be suitable for clinical use,' Dr Studer says. 'The process involves careful adaptations in cell manufacturing, scale-up and safety testing. We expect completion of those studies within the next three to four years, the minimum time frame required for initiating studies potentially in human patients. We are very fortunate to be the only non-EU member of NEUROSTEMCELL ... My lab has greatly benefited from the collaborative and interactive environment, and the shared mission helped in driving the project forward.'

The NEUROSTEMCELL consortium comprises experts from Denmark, France, Germany, Italy, Sweden, the United Kingdom and the United States.


Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also

NEUROSTEMCELL
FP7 Research in Health
'Study uncovers new Parkinson's gene'





  Top   Research Information Center